Updates are available Correction dated 2023-03-14
Click to view Correction: https://doi.org/10.1007/s40257-023-00766-8
-
Authors
Hodak, Emmilia https://orcid.org/0000-0002-1645-8038
Geskin, Larisa
Guenova, Emmanuella
Ortiz-Romero, Pablo L.
Willemze, Rein
Zheng, Jie
Cowan, Richard
Foss, Francine
Mangas, Cristina
Querfeld, Christiane
-
Funding
Funding for this research was provided by:
Helsinn (Helsinn Healthcare SA)
- License Information
-
More Information
Article History
Accepted: 19 September 2022
First Online: 18 November 2022
Change Date: 14 March 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s40257-023-00766-8
Declarations
:
: Helsinn Healthcare SA.
: EH has served on scientific advisory boards of Actelion, Helsinn, Recordati Rare Diseases and Takeda, and speakers’ bureaus for Helsinn, Rafa and Takeda. LG has received research support from Helsinn Group, J&J, Mallinckrodt, Kyowa Kirin, Soligenix, Innate, miRagen, Galderma, Merck, BMS and Stratpharma; and has served on speakers’ bureaus for Helsinn Group and J&J, and scientific advisory boards for Helsinn Group, J&J, Mallinckrodt, Sanofi, Regeneron and Kyowa Kirin. EG has been a member of the scientific advisory board of Scailyte AG and has received grants and personal fees from Helsinn Healthcare, Kyowa Hakko Kirin and Takeda; and personal fees from Mallinckrodt Pharmaceuticals, Recordati, Novartis and Sanofi. PLO-R has served on advisory boards for Recordati Rare Diseases, Helsinn, 4SC, Innate Pharma, Kyowa Pharma Chemical Co., Takeda, miRagen Therapeutics and Actelion. RW has been a member of the scientific advisory board of Helsinn. JZ declares no conflicts of interest. RC has served as a consultant for Kyowa Kirin and as a member of the scientific advisory board for Helsinn Healthcare. FF has served as a consultant for Kyowa and Mallinkrodt. CM has served on advisory boards for Novartis, Helsinn, Bristol Myers Squibb, Sanofi and Pierre Fabre. CQ has served on advisory board/scientific committees for Helsinn, Bioniz, miRagen, Trillium and Kyowa Kirin; and has received research funding from Celgene.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: Prof. Hodak had full access to all the materials in the article and takes responsibility for the integrity and the accuracy of the analysis. All authors contributed to the study design and interpretation and reviewed and approved all manuscript drafts, including the final draft.
